Skip to main content

Table 5 Best overall response a by TIMP-1 protein status b

From: TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

  TIMP-1 Positive TIMP-1 Negative
Response No. (%) No. (%)
CR 4 (3.0) 2 (6.3)
PR 46 (34.8) 9 (28.1)
Total responses 50 (37.9) 11 (34.4)
(95% CI) (24.2 to 40.8)    (30.7 to 69.4)
SD 56 (42.4) 15 (46.9)
PD 15 (11.4) 5 (15.6)
Unknown 11 (8.3) 1 (3.1)
Total 132   32  
  1. aMeasurable disease (n = 164).
  2. bTotal responses, Fisher's exact test P =0.84.
  3. Abbreviations: CI Confidence interval, CR Complete response, PD Progressive disease, PR Partial response, SD Stable disease, TIMP-1 Tissue inhibitor of metalloproteinases-1.